3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Mantle-Cell
6
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Lymphoma
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Interventions
Rituximab
8
Vemurafenib
4
Cyclophosphamide
4
Cladribine
4
Specimen Handling
3
Diphenhydramine
3
Biopsy
3
Acetaminophen
3
obinutuzumab
2
ibrutinib
2
fludarabine phosphate
2
fludarabine
2
binimetinib
2
Dexamethasone
2
Calcium Dobesilate
2
CT-P10
2
Bendamustine Hydrochloride
2
venetoclax
1
tovorafenib
1
polatuzumab vedotin
1
pembrolizumab
1
immunotoxin HA22
1
encorafenib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
brexucabtagene autoleucel
1
auricularum
1
acalabrutinib
1
Whole-Body Irradiation
1
Valganciclovir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Hairy Cell
×
brexucabtagene autoleucel
×
1 year
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts